Bristol Myers Squibb (CELG-RI) Share-based Compensation (2009 - 2026)

Bristol Myers Squibb has disclosed Share-based Compensation across 18 years of filings, most recently posting $146.0 million for Q1 2026.

• In Q1 2026, Share-based Compensation rose 1.39% year-over-year to $146.0 million; the TTM figure through Mar 2026 stood at $555.0 million (up 7.14% YoY), while the FY2025 annual figure was $553.0 million, up 9.07% from the prior year.
• Share-based Compensation advanced to $146.0 million in Q1 2026, from $133.0 million in the prior quarter.
• Over the last five years, Share-based Compensation for CELG-RI reached as high as $146.0 million in Q1 2026 and fell as low as $107.0 million in Q1 2022.
• The 5-year median for Share-based Compensation is $129.0 million (2024), against an average of $128.3 million.
• Annual changes were most pronounced in 2022 — Share-based Compensation fell 29.14% — and 2023, when it advanced 18.1%.
• A 5-year view of Share-based Compensation shows it stood at $119.0 million in 2022, then advanced by 6.72% to $127.0 million in 2023, then declined by 5.51% to $120.0 million in 2024, then increased by 10.83% to $133.0 million in 2025, then advanced by 9.77% to $146.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $146.0 million, $133.0 million, and $139.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.